ERIC JONASCH to Infusions, Intravenous
This is a "connection" page, showing publications ERIC JONASCH has written about Infusions, Intravenous.
Connection Strength
0.264
-
Phase II Study of Carfilzomib in Patients With Refractory Renal Cell Carcinoma. Clin Genitourin Cancer. 2019 12; 17(6):451-456.
Score: 0.141
-
A phase II trial of gemcitabine plus capecitabine for metastatic renal cell cancer previously treated with immunotherapy and targeted agents. J Urol. 2008 Sep; 180(3):867-72; discussion 872.
Score: 0.066
-
Phase II trial of pemetrexed plus gemcitabine in patients with locally advanced and metastatic nonclear cell renal cell carcinoma. Am J Clin Oncol. 2013 Oct; 36(5):450-4.
Score: 0.024
-
A phase II study of the efficacy and safety of AMG 102 in patients with metastatic renal cell carcinoma. BJU Int. 2011 Sep; 108(5):679-86.
Score: 0.019
-
Phase II study of capecitabine combined with gemcitabine in the treatment of androgen-independent prostate cancer previously treated with taxanes. Cancer. 2006 May 15; 106(10):2143-7.
Score: 0.014